211 related articles for article (PubMed ID: 18971528)
1. Alteration of serum soluble endoglin levels after the onset of preeclampsia is more pronounced in women with early-onset.
Hirashima C; Ohkuchi A; Matsubara S; Suzuki H; Takahashi K; Usui R; Suzuki M
Hypertens Res; 2008 Aug; 31(8):1541-8. PubMed ID: 18971528
[TBL] [Abstract][Full Text] [Related]
2. Angiogenic biomarkers for prediction of early preeclampsia onset in high-risk women.
Moore Simas TA; Crawford SL; Bathgate S; Yan J; Robidoux L; Moore M; Maynard SE
J Matern Fetal Neonatal Med; 2014 Jul; 27(10):1038-48. PubMed ID: 24066977
[TBL] [Abstract][Full Text] [Related]
3. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia.
Baumann MU; Bersinger NA; Mohaupt MG; Raio L; Gerber S; Surbek DV
Am J Obstet Gynecol; 2008 Sep; 199(3):266.e1-6. PubMed ID: 18771978
[TBL] [Abstract][Full Text] [Related]
4. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.
Levine RJ; Lam C; Qian C; Yu KF; Maynard SE; Sachs BP; Sibai BM; Epstein FH; Romero R; Thadhani R; Karumanchi SA;
N Engl J Med; 2006 Sep; 355(10):992-1005. PubMed ID: 16957146
[TBL] [Abstract][Full Text] [Related]
5. Soluble endoglin for the prediction of preeclampsia in a high risk cohort.
Maynard SE; Moore Simas TA; Bur L; Crawford SL; Solitro MJ; Meyer BA
Hypertens Pregnancy; 2010; 29(3):330-41. PubMed ID: 20670156
[TBL] [Abstract][Full Text] [Related]
6. Soluble endoglin and transforming growth factor-beta1 in women who subsequently developed preeclampsia.
Lim JH; Kim SY; Park SY; Lee MH; Yang JH; Kim MY; Chung JH; Lee SW; Ryu HM
Prenat Diagn; 2009 May; 29(5):471-6. PubMed ID: 19253312
[TBL] [Abstract][Full Text] [Related]
7. Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia.
Chaiworapongsa T; Romero R; Korzeniewski SJ; Kusanovic JP; Soto E; Lam J; Dong Z; Than NG; Yeo L; Hernandez-Andrade E; Conde-Agudelo A; Hassan SS
Am J Obstet Gynecol; 2013 Apr; 208(4):287.e1-287.e15. PubMed ID: 23333542
[TBL] [Abstract][Full Text] [Related]
8. Maternal serum soluble endoglin at 30-33 weeks in the prediction of preeclampsia.
Lai J; Syngelaki A; Poon LC; Nucci M; Nicolaides KH
Fetal Diagn Ther; 2013; 33(3):149-55. PubMed ID: 23154616
[TBL] [Abstract][Full Text] [Related]
9. Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion.
Stepan H; Geipel A; Schwarz F; Krämer T; Wessel N; Faber R
Am J Obstet Gynecol; 2008 Feb; 198(2):175.e1-6. PubMed ID: 18226617
[TBL] [Abstract][Full Text] [Related]
10. An analysis on the roles of angiogenesis-related factors including serum vitamin D, soluble endoglin (sEng), soluble fms-like tyrosine kinase 1 (sFlt1), and vascular endothelial growth factor (VEGF) in the diagnosis and severity of late-onset preeclampsia.
Cim N; Kurdoglu M; Ege S; Yoruk I; Yaman G; Yildizhan R
J Matern Fetal Neonatal Med; 2017 Jul; 30(13):1602-1607. PubMed ID: 27658884
[TBL] [Abstract][Full Text] [Related]
11. [Serum soluble Endoglin, plasma endothelin-1 and coagulation function in early onset severe preeclampsia with organ dysfunction].
Zhang LJ; Han YH; Han YZ
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2010 Jun; 22(6):371-4. PubMed ID: 20594474
[TBL] [Abstract][Full Text] [Related]
12. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia.
Rana S; Karumanchi SA; Levine RJ; Venkatesha S; Rauh-Hain JA; Tamez H; Thadhani R
Hypertension; 2007 Jul; 50(1):137-42. PubMed ID: 17515455
[TBL] [Abstract][Full Text] [Related]
13. Endoglin in pregnancy complicated by fetal intrauterine growth restriction in normotensive and preeclamptic pregnant women: a comparison between preeclamptic patients with appropriate-for-gestational-age weight infants and healthy pregnant women.
Laskowska M; Laskowska K; Oleszczuk J
J Matern Fetal Neonatal Med; 2012 Jun; 25(6):806-11. PubMed ID: 21793708
[TBL] [Abstract][Full Text] [Related]
14. Serum sFlt1:PlGF ratio, PlGF, and soluble endoglin levels in gestational proteinuria.
Ohkuchi A; Hirashima C; Matsubara S; Suzuki H; Takahashi K; Usui R; Suzuki M
Hypertens Pregnancy; 2009 Feb; 28(1):95-108. PubMed ID: 19165674
[TBL] [Abstract][Full Text] [Related]
15. Circulating soluble endoglin and placental abruption.
Signore C; Mills JL; Qian C; Yu KF; Rana S; Karumanchi SA; Levine RJ
Prenat Diagn; 2008 Sep; 28(9):852-8. PubMed ID: 18702104
[TBL] [Abstract][Full Text] [Related]
16. Soluble endoglin as a second-trimester marker for preeclampsia.
Robinson CJ; Johnson DD
Am J Obstet Gynecol; 2007 Aug; 197(2):174.e1-5. PubMed ID: 17689640
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy.
Salahuddin S; Lee Y; Vadnais M; Sachs BP; Karumanchi SA; Lim KH
Am J Obstet Gynecol; 2007 Jul; 197(1):28.e1-6. PubMed ID: 17618745
[TBL] [Abstract][Full Text] [Related]
18. Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction.
Stepan H; Krämer T; Faber R
J Clin Endocrinol Metab; 2007 Jul; 92(7):2831-4. PubMed ID: 17426082
[TBL] [Abstract][Full Text] [Related]
19. Increased plasma soluble fms-like tyrosine kinase 1 and endoglin levels in pregnancies complicated with preeclampsia.
Chedraui P; Lockwood CJ; Schatz F; Buchwalder LF; Schwager G; Guerrero C; Escobar GS; Hidalgo L
J Matern Fetal Neonatal Med; 2009 Jul; 22(7):565-70. PubMed ID: 19350449
[TBL] [Abstract][Full Text] [Related]
20. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies.
Powers RW; Jeyabalan A; Clifton RG; Van Dorsten P; Hauth JC; Klebanoff MA; Lindheimer MD; Sibai B; Landon M; Miodovnik M;
PLoS One; 2010 Oct; 5(10):e13263. PubMed ID: 20948996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
